Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Complained To Woodcock About Exondys 51 Review Early And Often

Sep 07 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community

May 25 2016

FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Sep 15 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Sarepta's Duchenne Treatment Likely Making Progress At FDA

Feb 08 2016

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.

Aug 22 2017

Moscicki, One Of US FDA's Industry Connections, Moves To PhRMA

Aug 30 2017

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture

Nov 04 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

United States Rare Diseases Drug Review Regulation FDA Leadership BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window